ライフサイエンスコーパス: cardiac troponin T

1 roponin (the NH(2) terminus (TnT-(1-153)) of cardiac troponin T).

2 (endo)plasmic reticulum Ca(2+) ATPase 1, and cardiac troponin T.

3 e populations as determined by expression of cardiac troponin T.

4 2a, and very little of the mature isoform of cardiac troponin T.

5 n heavy chain, myosin binding protein C, and cardiac troponin T.

6 coronary syndrome (NSTE-ACS) and an elevated cardiac troponin T.

7 1,200 patients with NSTE-ACS and an elevated cardiac troponin T.

8 gy in patients with NSTE-ACS and an elevated cardiac troponin T.

9 -day mortality, better than high-sensitivity cardiac troponin T.

10 exon 5 with the adjoining exon 6 from avian cardiac troponin-T.

11 atric dosing resulted in fewer elevations of cardiac troponin T (0 of 12 piglets vs. 6 of 11 piglets,

12 women; 21.5% with elevated high-sensitivity cardiac troponin T; 17.7% with elevated NT-proBNP) with

13 144 patients with elevated high-sensitivity cardiac troponin T, 31 had signs of MI and 113 did not.

14 Levels of cardiac troponin T, a biomarker of cardiomyocyte injury,

15 Adding high-sensitive cardiac troponin T absolute change to the Revised Cardia

16 segment results in conformational changes in cardiac troponin T, an altered binding affinity for trop

17 protein expression of cardiomyogenic markers cardiac troponin T and alpha-smooth muscle actin in CPCe

18 urs within the tropomyosin-binding domain of cardiac troponin T and alters the charge of the residue.

19 Measurement of the cardiac troponins, cardiac troponin T and cardiac troponin I, using sensiti

20 onal antibodies (mAbs) raised against bovine cardiac troponin T and chicken tropomyosin to visualize

21 assess the usefulness of baseline levels of cardiac troponin T and CK-MB and the electrocardiographi

22 f muscle-enriched miRNAs with high-sensitive cardiac troponin T and cMyBP-C returned the highest area

23 High-sensitivity cardiac troponin T and creatine kinase-myocardial band w

24 of these transcripts paralleled the rise in cardiac troponin T and decayed at 30 days.

25 he 2 well-known biomarkers (high-sensitivity cardiac troponin T and N-terminal pro-brain natriuretic

26 ment of beating sheets of cells that express cardiac troponin T and show a full range of action poten

27 this study was to investigate the utility of cardiac troponin T and troponin I for predicting outcome

28 Cardiac troponin T and troponin I have shown promise as

29 The ability of cardiac troponin T and troponin I to predict risk for su

30 Cardiac Troponins (T and I) are well established protein

31 Cardiac troponins T and I (cTnT, cTnI) are highly specif

32 ro-brain natriuretic peptide (NT-proBNP) and cardiac troponins T and I (TnT and TnI) for prognosticat

33 defects in beta-cardiac myosin heavy chain, cardiac troponin T, and alpha-tropomyosin account for >

34 B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive prot

35 B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive prot

36 e protein, procalcitonin, ferritin, D-dimer, cardiac troponin T, and N-terminal pro-B-type natriureti

37 min, beta-myosin heavy chain, alpha-actinin, cardiac troponin T, and phospholamban at levels comparab

38 ocytes, as identified by immunostaining with cardiac troponin-T antibody.

39 Very low levels of cardiac troponin T are associated with an increased risk

40 Very low but detectable levels of cardiac troponin T are associated with total CVD and CVD

41 ype natriuretic peptide and high-sensitivity cardiac troponin T are frequently elevated in severe sep

42 coding the thin-filament contractile protein cardiac troponin T are responsible for 15% of all cases

43 per reference limit for the high-sensitivity cardiac troponin T assay (hs-cTnT) in 3 large independen

44 With the widespread use of high-sensitive cardiac troponin T assays, positive tests become frequen

45 ide, alpha- and beta-myosin heavy chain, and cardiac troponin T) by day 3 with subsequent progression

46 Mutations in the gene encoding human cardiac troponin T can cause familial hypertrophic cardi

47 onal analysis of all protein coding exons of cardiac troponin T, cardiac troponin I, alpha-tropomyosi

48 17.8 ng/L and a perioperative high-sensitive cardiac troponin T change greater than or equal to 6.3 n

49 The risk predictive power of high-sensitive cardiac troponin T change in addition to the Revised Car

50 We measured the cardiac troponin T concentration at baseline with a high

51 The cardiac troponin T concentration was an independent pred

52 terminal pro-B-type natriuretic peptide, and cardiac troponin T concentrations in multivariate analys

53 type natriuretic peptide or high-sensitivity cardiac troponin T concentrations were independently ass

54 ans, and patients were masked to study serum cardiac troponin-T concentrations and echocardiographic

55 s, serial endomyocardial biopsies, and serum cardiac troponin-T concentrations were obtained from 68

56 Mutations in the gene that encode cardiac troponin T (cTnT) account for approximately 15%

57 intronic elements (called MSEs) flanking the cardiac troponin T (cTNT) alternative exon 5 and promote

58 Cardiac troponin T (cTnT) and B-type natriuretic peptide

59 Cardiac troponin T (cTnT) and C-reactive protein (CRP) a

60 Cardiac troponin T (cTnT) and I (cTnI) are cardiac marke

61 Cardiac troponin T (cTnT) and I elevations are associate

62 f two pre-mRNAs that are misregulated in DM, cardiac troponin T (cTNT) and insulin receptor (IR).

63 Biomarkers included cardiac troponin T (cTnT) and N-terminal pro-brain natri

64 -specific acute cardiac stress (by measuring cardiac troponin T (cTnT) and N-terminal prohormone of b

65 Cardiac troponin T (cTnT) and sensitive cardiac troponin

66 However, it is not clear whether cardiac troponin T (cTnT) and troponin I (cTnI) are equi

67 Detectable levels of cardiac troponin T (cTnT) are strongly associated with s

68 The release of cardiac troponin T (cTnT) as a biomarker of doxorubicin-

69 r group previously identified elevated serum cardiac troponin T (cTnT) as the most powerful predictor

70 We investigated the utility of cardiac troponin T (cTnT) blood levels (CARDIAC T ELISA

71 Multiple mutations in cardiac troponin T (cTnT) can cause familial hypertrophi

72 eins including myosin heavy chain (MyHC) and cardiac troponin T (cTnT) cause a dominant genetic heart

73 The prevalence and determinants of cardiac troponin T (cTnT) elevation in the general popul

74 quantitative ST-segment depression (ST) and cardiac troponin T (cTnT) elevation.

75 Alternative splicing of cardiac troponin T (cTNT) exon 5 undergoes a development

76 (ETR-3/NAPOR/BRUNOL3) promotes inclusion of cardiac troponin T (cTNT) exon 5 via binding between pos

77 to determine whether there is immunoreactive cardiac troponin T (cTnT) expression in diseased skeleta

78 The chicken cardiac troponin T (cTNT) gene contains a single 30-nucl

79 nother purine-rich enhancer from the chicken cardiac troponin T (cTNT) gene for the ability to regula

80 ative exon 5 of the striated muscle-specific cardiac troponin T (cTNT) gene is included in mRNA from

81 Striated muscle-specific expression of the cardiac troponin T (cTNT) gene is mediated through two M

82 Insulin Receptor (IR) gene and exon 5 of the cardiac Troponin T (cTNT) gene.

83 Abstract Cardiac troponin T (cTnT) has a highly acidic extended N

84 ical and biological significance of elevated cardiac troponin T (cTnT) in patients with neuromuscular

85 Cardiac troponin T (cTnT) is a central component of the

86 Cardiac troponin T (cTnT) is a key component of contract

87 Cardiac troponin T (cTnT) is a myofibrillar protein esse

88 Cardiac troponin T (cTnT) is a phosphoprotein that modul

89 Cardiac troponin T (cTnT) is an essential component of t

90 The thin filament protein cardiac troponin T (cTnT) is an important regulator of m

91 Cardiac Troponin T (cTnT) is one prominent substrate thr

92 e investigated the physiological role of the cardiac troponin T (cTnT) isoforms in the presence of hu

93 Exactly how FHC-associated mutations in cardiac troponin T (cTnT) lead to impaired cardiac funct

94 The baseline cardiac troponin T (cTnT) level strongly predicts short-

95 prospectively evaluated the relation between cardiac troponin T (cTnT) level, the presence and severi

96 Changes in cardiac troponin T (cTnT) levels are required for the di

97 erified assumption that chronically elevated cardiac troponin T (cTnT) levels fluctuate randomly arou

98 Elevated plasma cardiac troponin T (cTnT) levels in patients with neurom

99 Serum creatine kinase-MB (CK-MB) and cardiac troponin T (cTnT) levels were measured before an

100 We evaluated whether cardiac troponin T (cTnT) measured with a new highly sen

101 a splice donor site mutation (trunc) in the cardiac troponin T (cTnT) model familial hypertrophic ca

102 of established interstitial fibrosis in the cardiac troponin T (cTnT) mouse model of human hypertrop

103 The hypertrophic cardiomyopathy-causing cardiac troponin T (cTnT) mutation Delta160Glu (Delta160

104 eporting the functional effects of the first cardiac troponin T (CTnT) mutation linked to infantile R

105 A novel double deletion in cardiac troponin T (cTnT) of two highly conserved amino

106 ial necrosis was assessed by measurements of cardiac troponin T (cTnT) on admission and 12 h after ad

107 CUG-BP was found to bind to the human cardiac troponin T (cTNT) pre-messenger RNA and regulate

108 MBNL1 controls the splicing of exon 5 in the cardiac troponin T (cTNT) pre-mRNA by competing directly

109 Regulated alternative splicing of avian cardiac troponin T (cTNT) pre-mRNA requires multiple int

110 st-procedure CK-MB, an isolated elevation in cardiac troponin T (cTnT) predicts long-term survival.

111 n discriminate ischemia from other causes of cardiac troponin T (cTnT) release.

112 s to determine whether different profiles of cardiac troponin T (cTnT) values assessed over time woul

113 embled on a screen-printed electrode for the cardiac troponin T (cTnT) was developed.

114 esent study was to evaluate whether elevated cardiac troponin T (cTnT) was independently associated w

115 The cDNA encoding the cardiac troponin T (cTnT) was isolated.

116 METHODS AND Cardiac troponin T (cTnT) was measured during the first

117 Repeated measures of highly sensitive cardiac troponin T (cTnT) were obtained in participants

118 iac injury are cardiac troponin I (cTnI) and cardiac troponin T (cTnT) which have been considered as

119 NT photodetector for an on-chip detection of cardiac troponin T (cTnT) with a detection limit of 12 p

120 isopropylacrylamide (PNIPAAm) functionalised cardiac troponin T (cTnT) with anti-cTnT.

121 splicing of TNNT2, the gene that encodes for cardiac troponin T (cTnT), a biomarker of myocardial inj

122 f body mass, heart rate, blood pressures and cardiac troponin T (cTnT), a biomarker of myocyte damage

123 interaction between LVH, low but detectable cardiac troponin T (cTnT), and elevated N-terminal pro-B

124 tic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (cTnT), and genetic analysis.

125 s insensitive to reconstitution of cTnI with cardiac troponin T (cTnT), cTnC, or cTnC and cTnT in the

126 Cardiac troponin T (cTnT), even at low concentrations, i

127 For the first time, we show that cardiac troponin T (cTnT), in part through its intrinsic

128 t of expression of a mutant (Arg92Gln) human cardiac troponin T (cTnT), known to cause HCM in humans,

129 globin (MYG), bovine serum albumin (BSA) and cardiac troponin T (cTnT), respectively.

130 Cardiac troponin T (cTnT), the tropomyosin binding subun

131 50%, and improved diastolic function in the cardiac troponin T (cTnT)-Q92 transgenic mouse model of

132 arcomeric AKAP (A-kinase anchoring protein), cardiac troponin T (cTnT).

133 n vitro with high substrate affinity but not cardiac troponin T (cTnT).

134 ption of a contractile protein gene encoding cardiac troponin T (cTnT).

135 t cardiac muscle normally expresses a single cardiac troponin T (cTnT).

136 he alternative splicing of exon 5 of chicken cardiac troponin T (cTnT).

137 ressing low levels of normal or mutant human cardiac troponin T (cTnT).

138 er Nkx2.5, or that of the myocardial marker, cardiac troponin T (cTnT).

139 rdial infarction, especially with the use of cardiac troponin T (cTnT).

140 tiation factor-15 (GDF-15), high-sensitivity cardiac troponin T (cTnT-hs) and haemoglobin, age, and p

141 We randomized 24 adult cardiac troponin T (cTnT-Q(92)) mice, which exhibit myoc

142 cardiograms and serial serum measurements of cardiac troponin T (cTnT; cardiac injury biomarker), N-t

143 the pathologic free light chains (p < 0.05), cardiac troponin-T (cTnT) (p < 0.01), and the Karnofsky

144 AT), matrix metalloproteinase-9 (MMP-9), and cardiac Troponin-T (cTnT) were evaluated by appropriate

145 expression of cardiac troponin-I (cTnI) and cardiac troponin-T (cTnT).

146 through the detection and quantification of cardiac Troponin-T (cTnT).

147 nano-gap device provides the capability for cardiac-troponin T (cTnT) measurements with co-existed 1

148 s screening of cardiac Troponin-I (cTnI) and cardiac-Troponin-T (cTnT) in a point-of-care sensor form

149 Pretransplant cardiac troponin T(cTnT(pre) ) is a significant predicto

150 (Ser532Pro and Phe764Leu) and a deletion in cardiac troponin T (deltaLys210) caused early-onset vent

151 eletion of the N-terminal variable region of cardiac troponin T demonstrates a novel mechanism by whi

152 e ESC 0/1-h algorithm using high-sensitivity cardiac troponin T embedded in routine clinical care and

153 Elevated cardiac troponin T even below traditional detection leve

154 ining the purine-rich splicing enhancer from cardiac troponin T exon 5.

155 ic cardiomyopathy caused by mutations in the cardiac troponin T gene (TNNT2) has been associated with

156 In the cardiac troponin T gene (TNNT2), a specific mutation (R9

157 f a 9-bp segment from intron 7 of the turkey cardiac troponin T gene may be responsible for the weake

158 A novel missense mutation in the cardiac troponin T gene was identified by direct sequenc

159 mano-Ward syndrome and long-QT syndrome, and cardiac troponin T gene, tnnt2, affected in human cardio

160 tively included six-nucleotide exon from the cardiac troponin T gene.

161 t was very similar to that of the endogenous cardiac troponin T gene.

162 A preoperative high-sensitive cardiac troponin T greater than or equal to 17.8 ng/L an

163 deaths compared with 29.5% among those with cardiac troponin T > or = 0.01 microg/L (p < .001).

164 43.7%, 33.8%, and 25.7% among patients with cardiac troponin T > or = 0.01 microg/L and 75.3%, 67.6%

165 , who experienced an event associated with a cardiac troponin T >99th percentile of a normal referenc

166 A total of 5460 patients had at least one cardiac troponin T >=0.01 ng/mL; 1365 of these patients

167 chronic myocardial injury (high-sensitivity cardiac troponin T >=6 ng/L] and stress (N-terminal pro-

168 GST) affinity tag at the N-terminus of human cardiac troponin T (hcTnT) and an intervening tobacco et

169 pe natriuretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated

170 anterior circulation and a high-sensitivity cardiac troponin T (hs-cTnT) acquired on the day of admi

171 ween serial measurements of high-sensitivity cardiac troponin T (hs-cTnT) and future events in HF.

172 High-sensitivity cardiac troponin T (hs-cTnT) and N-terminal B-type natri

173 Although small elevations of high-sensitive cardiac troponin T (hs-cTnT) are associated with inciden

174 High-sensitivity assays for cardiac troponin T (hs-cTnT) are sometimes used to rapid

175 tional level, with elevated high-sensitivity cardiac troponin T (hs-cTnT) concentrations (>/=14 ng/L)

176 tic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) concentrations were measure

177 rognostic value of baseline high-sensitivity cardiac troponin T (hs-cTnT) elevation in SCAD patients

178 ated hemoglobin (HbA1c) and high-sensitivity cardiac troponin T (hs-cTnT) in 9,661 participants free

179 sponse to mental stress and high-sensitivity cardiac troponin T (hs-cTnT) in healthy older individual

180 implications of introducing high-sensitivity cardiac troponin T (hs-cTnT) into clinical practice and

181 High-sensitivity cardiac troponin T (hs-cTnT) is a biomarker of cardiovas

182 f an undetectable (<5 ng/l) high-sensitivity cardiac troponin T (hs-cTnT) level and an electrocardiog

183 hesized that any detectable high-sensitivity cardiac troponin T (hs-cTnT) level is associated with ad

184 s are preferable when using high-sensitivity cardiac troponin T (hs-cTnT) levels in the diagnosis of

185 Their high-sensitivity cardiac troponin T (hs-cTnT) levels were measured.

186 econdary endpoints included high-sensitivity cardiac troponin T (hs-cTnT) on day 4, left ventricular

187 CVD) but elevated levels of high-sensitivity cardiac troponin T (hs-cTnT) or N-terminal pro-B-type na

188 oninferiority of a 0/1-hour high-sensitivity cardiac troponin T (hs-cTnT) protocol in comparison with

189 ge, as assessed by elevated high-sensitivity cardiac troponin T (hs-cTnT) test results.

190 A 1-h algorithm based on high-sensitivity cardiac troponin T (hs-cTnT) testing at presentation and

191 Thus, we assessed whether high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical my

192 B-type natriuretic peptide, high-sensitivity cardiac troponin T (hs-cTnT), and high-sensitivity cardi

193 uretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and low-density lipoprotei

194 uretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), Cystatin-C (Cys-C), high-s

195 oponin T, measured by a new highly sensitive cardiac troponin T (hs-cTnT), may reflect ischemia witho

196 ge, as assessed by elevated high-sensitivity cardiac Troponin T (hs-cTnT).

197 ognostic merit with that of high-sensitivity cardiac troponin T (hs-TnT).

198 rdial Infarction) evaluated high-sensitivity cardiac troponin-T (hs-cTnT) in a 1-hour acute myocardia

199 ning with a biomarker (e.g. high sensitivity cardiac troponin T [hs-cTnT] or B-type natriuretic pepti

200 th myocardial damage (using high-sensitivity cardiac troponin-T [hs-cTnT]) and with coronary heart di

201 chain, myosin light chain 1/2, tropomyosin, cardiac troponins (T, I, C), and the trimeric troponin c

202 of wild-type (WT) cTn and cTn containing WT cardiac troponin T/I + cardiac troponin C (cTnC) D65A (a

203 ponin I was measured in 61,379 patients, and cardiac troponin T in 7880 patients (both proteins were

204 n 97.4% of the patients and high-sensitivity cardiac troponin T in 84.5%, with higher concentrations

205 sing serial measurements of high-sensitivity cardiac troponin T in clinical routine.

206 Despite the importance of cardiac troponin T in human disease, its loss-of-functio

207 was defined as an absolute high-sensitivity cardiac troponin T increase of >/=14 ng/L from preoperat

208 l prospective measurements were performed of cardiac troponin T, indexes of NO production (NO(2)(-) a

209 For a third trait, cardiac troponin T, investigation of regulatory domains

210 Cardiac troponin T is a sensitive and specific marker of

211 Cardiac troponin-T is a sensitive marker of myocardial d

212 n of force development, the four known human cardiac troponin T isoforms, TnT1 (all exons present), T

213 Deletion of the 14 C-terminal residues of cardiac troponin T leads to hypertrophic cardiomyopathy.

214 The cardiac troponin T level is a powerful, independent risk

215 level of 1.0 microg per liter or higher or a cardiac troponin T level of 0.1 microg per liter or high

216 acute chest pain, elevated high-sensitivity cardiac troponin T levels (>14 ng/l), and inconclusive e

217 Serum high-sensitivity cardiac troponin T levels and electrocardiograms were ob

218 Whether high-sensitivity cardiac troponin T levels are associated with adverse ca

219 However, changes in cardiac troponin T levels during the infusion did not di

220 nts with suspected acute coronary syndromes, cardiac troponin T levels have prognostic value.

221 acrophages, almost complete normalization of cardiac troponin T levels in serum and of left ventricul

222 Cardiac troponin T levels predict short-term prognosis i

223 Cardiac troponin T levels were measured using both the s

224 In patients with NSTE-ACS and elevated cardiac troponin T levels, an early invasive strategy ha

225 Cardiac troponin T levels, CK-MB levels, and electrocard

226 ng hospitalization, 12.5% of patients with a cardiac troponin T < 0.01 microg/L suffered deaths compa

227 /L and 75.3%, 67.6%, and 62.9% in those with cardiac troponin T < 0.01 microg/L, respectively (p < .0

228 normal biomarkers (hs-cTnT (high sensitivity cardiac troponin-T) <6 ng/L and NT-proBNP (N-terminal pr

229 We also found that Max was a part of the cardiac troponin T M-CAT-TEF-1 complex even when the DNA

230 ion may impair the prognostic value, because cardiac troponin T may be cleared by the kidney.

231 We also reconstituted mouse cardiac troponin T (McTnT) N-terminal deletion mutants,

232 eri-procedural increases of high-sensitivity cardiac troponin T (mean: 9.9 ng/ml, range: 2.7 to 19.0

233 High levels of cardiac troponin T, measured by a highly sensitive assay

234 ive and 24-hour postoperative high-sensitive cardiac troponin T measurements and the respective chang

235 ac investigations including high-sensitivity cardiac troponin T measurements at later time points or

236 Pre- and postoperative high-sensitive cardiac troponin T measurements demonstrated a majority

237 Compared with the cardiac troponin T method, hsTnT detected 27% more ACS c

238 say (hsTnT) and compared with a conventional cardiac troponin T method.

239 CELF6 activates exon inclusion of a cardiac troponin T minigene in transient transfection as

240 eins specifically activate exon inclusion of cardiac troponin T minigenes in vivo via muscle-specific

241 lure express an unusual low molecular weight cardiac troponin T missing 11 amino acids due to the spl

242 tide enhancer that has similarities with the cardiac Troponin T MSE3 enhancer, and a potentially nove

243 In addition, two mouse cardiac troponin T mutants (TnT(1-44Delta) and TnT(45-74

244 Thus, the novel cardiac troponin T mutation Arg141Trp is responsible for

245 ion in FHC caused by beta-cardiac myosin and cardiac troponin T mutations.

246 In comparison, neither cardiac troponin T nor phospholamban was detected in the

247 Human HLA-ABC antigen and cardiac troponin T or Nkx2.5 were used as markers for ca

248 sus without either elevated high-sensitivity cardiac troponin T or NT-proBNP had a 10-year CV inciden

249 Elevations in high-sensitivity cardiac troponin T or NT-proBNP identify individuals wit

250 native splicing patterns (for example, human cardiac troponin T) or affects other aspects of RNA biol

251 e have asked whether serum concentrations of cardiac troponin-T predict development of coronary arter

252 Expression of the exon 8-deleted cardiac troponin T prior to the development of cardiomyo

253 combinase expressed under the control of the cardiac troponin T promoter resulted in death by E12.5;

254 rdiac-selective expression of EcSOD from the cardiac troponin-T promoter after systemic administratio

255 ellular superoxide dismutase (EcSOD) via the cardiac troponin-T promoter would protect the mouse hear

256 Of those tested, only the hANP and cardiac troponin T promoters were suppressed by Ras.

257 10(-8)) in the gene TNNT2, which encodes the cardiac troponin T protein itself.

258 expression, transgenic mice carrying the rat cardiac troponin T proximal promoter (-497 bp from the t

259 igenic mice, turned on and off expression of cardiac troponin T-Q92 (cTnT-Q92), responsible for human

260 ociation rates in fully reconstituted WT and cardiac troponin T R92L and R92W thin filaments.

261 s, we used 2 mouse models of sarcomeric HCM (cardiac troponin T R92L and R92W) with differential myoc

262 and methylprednisolone significantly reduced cardiac troponin T release and the number of allograft i

263 nhanced myocardial damage evidenced by serum cardiac troponin T release in the rat and mouse cardiac

264 nges in markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C),

265 ific antigens cardiac myosin heavy chain and cardiac troponin T, respectively (immunocytochemistry),

266 Cardiac troponin-T sensitively reflects myocardial damag

267 pro-brain natriuretic peptide (pro-BNP), and cardiac troponin T showed significant linear trends for

268 Immunohistochemistry, using a cardiac troponin T-specific monoclonal antibody, and ult

269 ificantly more cardiomyocytes, determined by cardiac troponin-T staining, in the MI zone of the QHG21

270 tions between or near residues 112 to 136 of cardiac troponin-T, the crucial TnT1 (N-terminal domain

271 enes encoding cardiac troponin I (TNNI3) and cardiac troponin T (TNNT2) caused altered troponin prote

272 RNAs including the Insulin Receptor (Insr), Cardiac Troponin T (Tnnt2), Lim Domain Binding 3 (Ldb3)

273 ted splicing of three CELF target pre-mRNAs, cardiac troponin T (Tnnt2), myotubularin-related 1 gene

274 eart and went on to examine the functions of cardiac troponin T (tnnt2).

275 ardiac troponin I (TNNI3p.98truncation ) and cardiac troponin T (TNNT2p.K217deletion ; also known as

276 estigated the prognostic value of detectable cardiac troponin T (TnT) and elevated N-terminal pro-B-t

277 ausing mutations associated with a truncated cardiac troponin T (TnT) and missense mutations in the b

278 The cardiac troponin T (TnT) I79N mutation has been linked t

279 The cardiac troponin T (TnT) I79N mutation has been linked t

280 Cardiac troponin T (TnT) is a highly sensitive cardiac b

281 The N-terminal variable region of cardiac troponin T (TnT) is a regulatory structure that

282 treated with adenovirus containing the adult cardiac troponin T (TnT) or cTnI cDNAs.

283 t to evaluate the prognostic significance of cardiac troponin T (TnT) serum levels after noncardiac s

284 le to the NH2-terminal portion of the bovine cardiac troponin T (TnT) subunit.

285 The C-terminal region of cardiac troponin T (TnT), a tropomyosin-associated prote

286 are mutations in the TNNT2 gene that encodes cardiac troponin T (TnT).

287 h no cardiovascular disease in our study had cardiac troponin T values above the current myocardial i

288 emoglobin A(1c), detectable high-sensitivity cardiac troponin T was associated with subsequent CVD (m

289 High-sensitivity cardiac troponin T was detectable (>/= 0.003 mug/L) in 4

290 Cardiac troponin T was detectable (>/=3.00 pg/mL) in 279

291 High-sensitivity cardiac troponin T was measured as a marker of myocardia

292 The level of high-sensitive cardiac troponin T was significantly associated with pre

293 ype natriuretic peptide and high-sensitivity cardiac troponin T were measured 1, 2, and 7 days after

294 Serial measurements of serum cardiac troponin T were obtained in 76 of 101 patients i

295 o cause HCM, both wild-type and mutant human cardiac troponin T were overexpressed in Escherichia col

296 Left ventricular structure and function and cardiac troponin-T were among the top predictors for inc

297 defect in the interactions between CTnC and cardiac troponin T, which are known to be necessary for

298 We measured cardiac troponin T with a highly sensitive assay (hs-cTn

299 hich most patients would have had a negative cardiac troponin T with older assays); and Group 4, thos

300 rmined pre- and postoperative high-sensitive cardiac troponin T with the occurrence of major adverse